Table 2.

Impact of different definitive regimens on the outcomes among patients with S. maltophilia-HAP via a WPS analysis

Outcome	Patients (n, %)		Univariate logistic analysis		Multivariate logistic analysis
			OR (95% CI)	P	*OR (95% CI)	P
30-day mortality	Entire cohort	126/307 (41.0)	1.104 (0.698–1.747)	0.671	1.124 (0.707–1.786)	0.622
	Immunocompromised	65/117 (55.6)	0.396 (0.176–0.892)	0.025	0.404 (0.170–0.962)	0.041
	Immunocompetent	61/190 (32.1)	1.597 (0.864–2.592)	0.135	1.349 (0.712–2.554)	0.359
	APACHE II score ≥ 15	92/193 (47.7)	0.471 (0.256–0.866)	0.015	0.494 (0.256–0.951)	0.035
	APACHE II score < 15	34/114 (29.8)	2.956 (1.290–6.770)	0.010	2.357 (0.820–6.677)	0.111
30-day clinical response	Entire cohort	167/307 (54.4)	0.999 (0.636–1.570)	0.996	0.987 (0.626–1.557)	0.956
	Immunocompromised	52/117 (44.4)	2.523 (1.121–5.674)	0.025	2.601 (1.088–6.218)	0.032
	Immunocompetent	115/190 (60.5)	0.709 (0.395–1.271)	0.248	0.833 (0.453–1.530)	0.555
	APACHE II score ≥ 15	95/193 (49.2)	2.128 (1.153–3.926)	0.016	2.096 (1.082–4.058)	0.028
	APACHE II score < 15	72/114 (63.2)	0.440 (0.201–0.965)	0.041	0.584 (0.212–1.608)	0.298
30-day microbiology eradiction ǂ	Entire cohort	131/272 (48.2)	1.049 (0.649–1.693)	0.846	1.035 (0.640–1.677)	0.888
	Immunocompromised	38/106 (35.8)	2.625 (1.049–6.569)	0.039	2.788 (1.027–7.567)	0.044
	Immunocompetent	93/166 (56.0)	0.827 (0.448–1.528)	0.544	0.955 (0.504–1.810)	0.887
	APACHE II score ≥ 15	79/175 (45.1)	2.199 (1.150–2.407)	0.017	2.256 (1.123–4.534)	0.022
	APACHE II score < 15	52/97 (53.6)	0.388 (0.168–0.896)	0.027	0.478 (0.164–1.397)	0.177

^*adjusted by WPS for treatment

ǂ35 patients didn't perform repeated culture of eligible respiratory tract samples